Skip to main content
. Author manuscript; available in PMC: 2013 Sep 23.
Published in final edited form as: J Alzheimers Dis. 2013 Jan 1;36(3):475–486. doi: 10.3233/JAD-122212

Figure 3.

Figure 3

Trial duration (A and B) and minimum surrogate treatment effects (C and D) required for 80% power in all non-demented subjects (A and C) and CDR 0.5 only non-demented subjects (B and D) populations. Estimates assume 1:1 randomization, one year accrual, and two-tailed testing at alpha = 0.05.